Pacanowski M - Search Results

1

Regulatory policy for the development of targeted therapies for low-frequency molecular subtypes of disease.

Schuck RN, Pacanowski M, Woodcock J, Zineh I. Schuck RN, et al. Among authors: pacanowski m. Nat Rev Drug Discov. 2018 Feb;17(2):79-80. doi: 10.1038/nrd.2017.231. Epub 2017 Dec 22. Nat Rev Drug Discov. 2018. PMID: 29269943 No abstract available.

2

Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension.

Pacanowski MA, Zineh I, Cooper-Dehoff RM, Pepine CJ, Johnson JA. Pacanowski MA, et al. Am J Hypertens. 2009 Jul;22(7):748-53. doi: 10.1038/ajh.2009.81. Epub 2009 Apr 30. Am J Hypertens. 2009. PMID: 19407804 Free PMC article. Clinical Trial.

3

Plasma Coenzyme Q10 Predicts Lipid-lowering Response to High-Dose Atorvastatin.

Pacanowski MA, Frye RF, Enogieru O, Schofield RS, Zineh I. Pacanowski MA, et al. J Clin Lipidol. 2008 Aug;2(4):289-97. doi: 10.1016/j.jacl.2008.05.001. J Clin Lipidol. 2008. PMID: 19649137 Free PMC article.

4

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol.

Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ. Welder G, et al. J Lipid Res. 2010 Sep;51(9):2714-21. doi: 10.1194/jlr.M008144. Epub 2010 Jun 5. J Lipid Res. 2010. PMID: 20525997 Free PMC article. Clinical Trial.

5

Learning from product labels and label changes: how to build pharmacogenomics into drug-development programs.

Surh LC, Pacanowski MA, Haga SB, Hobbs S, Lesko LJ, Gottlieb S, Papaluca-Amati M, Patterson SD, Hughes AR, Kim MJ, Close SL, Mosteller M, Zineh I, Dechairo B, Cohen NA. Surh LC, et al. Among authors: pacanowski ma. Pharmacogenomics. 2010 Dec;11(12):1637-47. doi: 10.2217/pgs.10.138. Pharmacogenomics. 2010. PMID: 21142906

6

Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study.

Price ET, Pacanowski MA, Martin MA, Cooper-DeHoff RM, Pepine CJ, Zineh I, Johnson JA. Price ET, et al. Among authors: pacanowski ma. Pharmacogenet Genomics. 2011 Jun;21(6):333-40. doi: 10.1097/FPC.0b013e3283452fec. Pharmacogenet Genomics. 2011. PMID: 21562465 Free PMC article.

7

Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration.

Zineh I, Pacanowski MA. Zineh I, et al. Pharmacotherapy. 2011 Aug;31(8):729-35. doi: 10.1592/phco.31.8.729. Pharmacotherapy. 2011. PMID: 21923598

8

Allopurinol pharmacogenetics: assessment of potential clinical usefulness.

Zineh I, Mummaneni P, Lyndly J, Amur S, La Grenade LA, Chang SH, Rogers H, Pacanowski MA. Zineh I, et al. Pharmacogenomics. 2011 Dec;12(12):1741-9. doi: 10.2217/pgs.11.131. Pharmacogenomics. 2011. PMID: 22118056

9

New genetic discoveries and treatment for hepatitis C.

Pacanowski M, Amur S, Zineh I. Pacanowski M, et al. JAMA. 2012 May 9;307(18):1921-2. doi: 10.1001/jama.2012.3516. JAMA. 2012. PMID: 22570460 No abstract available.

10

Biomarkers to improve the benefit/risk balance for approved therapeutics: a US FDA perspective on personalized medicine.

Sapsford KE, Tezak Z, Kondratovich M, Pacanowski MA, Zineh I, Mansfield E. Sapsford KE, et al. Among authors: pacanowski ma. Ther Deliv. 2010 Nov;1(5):631-41. doi: 10.4155/tde.10.62. Ther Deliv. 2010. PMID: 22833953

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

76 results

Search Page

Filters